When endometrial cancer returns or reaches an advanced stage, time becomes the most precious resource—and new data suggests that adding immunotherapy to standard chemotherapy can meaningfully extend it. In a prolonged follow-up analysis of the NRG Oncology GY018 trial, presented at the 2026 American Society of Clinical Oncology Annual Meeting, patients with advanced or recurrent endometrial cancer who received pembrolizumab combined with carboplatin and paclitaxel chemotherapy experienced sustained survival benefits compared to those receiving chemotherapy alone, even when many control-group patients later received immunotherapy on their own.
The trial enrolled 809 patients randomly assigned to receive either pembrolizumab or placebo alongside standard chemotherapy. The findings matter because endometrial cancer—particularly in its advanced or recurrent forms—has historically offered limited treatment options and poor outcomes. Dr. Ramez N. Eskander of the University of California, San Diego, who led the research, emphasized that this represents a meaningful shift: "The fact that the survival advantage persisted in the dMMR and pMMR EC populations adds great confidence to the use of pembrolizumab in combination with chemotherapy in treatment of appropriately selected patients, irrespective of MMR status."
The most striking results emerged in the dMMR (mismatch repair deficient) cohort. At 48 months, 79% of patients who received pembrolizumab upfront were still alive, compared to 60% of those who received placebo—a hazard ratio of 0.56. This advantage persisted despite the fact that at least 93% of the control-group patients later received immunotherapy as follow-up treatment, meaning the early incorporation of the drug provided a substantial edge even when accounting for subsequent interventions.
In the pMMR (mismatch repair proficient) population, the median overall survival reached 44.4 months for patients receiving pembrolizumab and chemotherapy versus 35.1 months for the placebo group—a 9.3-month difference. Though this benefit fell just short of statistical significance, it remained clinically notable, and the pattern held firm even though 81% of control patients eventually received post-study immunotherapy. The persistence of this benefit despite delayed immunotherapy access in the control arm suggests that giving pembrolizumab earlier, rather than waiting, may provide the greatest clinical impact.
The data were analyzed with an April 14, 2026 cutoff, providing information fractions of 43% in the dMMR cohort and 82% in the pMMR cohort. The findings were published in Nature Medicine alongside the conference presentation, lending weight to their clinical relevance.
For patients and oncologists navigating advanced endometrial cancer, these results offer something rare: evidence that a drug combination can move the needle on survival across different patient populations, regardless of mismatch repair status. The trial demonstrates that the immunotherapy benefit isn't erased by the fact that many patients will eventually access these drugs anyway—suggesting genuine, durable benefit from early treatment. As endometrial cancer continues to challenge the field, this sustained survival signal represents meaningful progress in a disease area historically marked by therapeutic stagnation.